Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Cash flows used in operating activities:
Net loss	$ (26,247)	$ (17,200)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock based compensation	5,738	4,627
Operating lease right-of-use asset	401	39
Depreciation	87	44
Amortization of premium on marketable debt securities	747
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	(1,848)	657
Other Assets, non-current	144
Accounts payable	489	200
Accrued expenses	(475)	(1,231)
Operating lease liabilities	(430)	(15)
Net cash used in operating activities	(21,394)	(12,879)
Cash flows (used in)/provided by investing activities:
Cash and restricted cash acquired in connection with the reverse merger with ArTara Therapeutics, Inc.		3,719
Purchase of marketable debt securities, available-for-sale	(99,574)
Purchase of property and equipment	(616)	(241)
Net cash (used in)/provided by investing activities	(100,190)	3,478
Cash flows (used in)/provided by financing activities:
Proceeds from - ArTara Private Placement, net of offering costs		1,867
Proceeds from - Common Stock in Proteon Private Placement, net of offering costs		12,413
Proceeds from - Series 1 Convertible Preferred Stock in Proteon Private Placement, net of offering costs		25,319
Repurchase of shares in connection with settlement of RSUs	(228)
Repayments under short-term debt		(741)
Net cash (used in)/provided by financing activities	(228)	38,858
Net (decrease)/increase in cash and cash equivalents and restricted cash	(121,812)	29,457
Cash and cash equivalents and restricted cash - beginning of year	169,393	564
Cash and cash equivalents and restricted cash - end of period	47,581	30,021
Cash paid for:
Interest		15
Income Taxes
Non-cash investing and financing activities:
Deferred offering costs recognized that were previously recorded in accrued expenses		122
Purchase of insurance agreement with notes payable		1,669
Common stock issued in connection with the reverse merger with ArTara Therapeutics, Inc.		$ 34,533